Life expectancy in rare histological prostate cancer subtypes
Survival differences in rare histological prostate cancer (PCa) subtypes relative to age-matched population-based controls are unknown. Within Surveillance, Epidemiology, and End Results database (2004-2020), newly diagnosed (2004-2015) PCa patients were identified. Relying on the Social Security Administration Life Tables (2004-2020) with 5 years of follow-up, age-matched population-based controls (Monte Carlo simulation) were simulated for each patient. Kaplan-Meier analyses addressed survival rates. Of 582,220 patients, 580,368 (99.68%) harbored acinar, 867 (0.15%) ductal, 534 (0.09%) neuroendocrine, 368 (0.07%) mucinous, and 83 (0.01%) signet ring cell carcinoma. The metastatic stage was most prevalent in neuroendocrine (62%). In the localized stage, the overall survival difference at 5 years of follow-up was greatest in neuroendocrine (22% vs. 72%), signet ring cell (78% vs. 84%), and ductal carcinoma (71% vs. 77%). In the locally advanced stage, overall survival difference was greatest in neuroendocrine (16% vs. 79%), signet ring cell (75% vs. 91%), ductal (78% vs. 84%), and mucinous carcinoma (84% vs. 90%). In the metastatic stage, the overall survival difference was greatest in neuroendocrine (3% vs. 81%), mucinous (26% vs. 84%), and acinar carcinoma (27% vs. 85%). Regardless of stage, neuroendocrine carcinoma patients exhibit the least favorable life expectancy compared with population-based controls. Conversely, all other rare histological PCa subtypes do not meaningfully affect life expectancy in localized or locally advanced stages, except for locally advanced signet ring cell adenocarcinoma.
Authors
- Zhe Tian (ORCID: https://orcid.org/0000-0002-9482-6473)
- Francesco Di Bello (ORCID: https://orcid.org/0000-0002-8585-3701)
- Felix K.‐H. Chun (ORCID: https://orcid.org/0000-0001-8486-9536)
- Carolin Siech (ORCID: https://orcid.org/0000-0002-5460-4171)
- Luis A. Kluth (ORCID: https://orcid.org/0000-0002-4629-4388)
- Alberto Briganti (ORCID: https://orcid.org/0000-0002-2178-0494)
- Nicola Longo (ORCID: https://orcid.org/0009-0009-3394-0596)
- Jordan A. Goyal (ORCID: https://orcid.org/0009-0006-4609-8981)
- Ottavio De Cobelli (ORCID: https://orcid.org/0000-0002-0699-8620)
- Letizia Maria Ippolita Jannello (ORCID: https://orcid.org/0000-0002-0612-0519)
- Philipp Mandel (ORCID: https://orcid.org/0000-0002-0760-7281)
- Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Mario de Angelis (ORCID: https://orcid.org/0009-0008-0494-7839)
- Stefano Puliatti (ORCID: https://orcid.org/0000-0002-1597-9595)
- Natali Rodriguez Peñaranda (ORCID: https://orcid.org/0009-0006-3057-3805)
- Pierre I. Karakiewicz
- Shahrokh F. Shariat
Institutions
- Al-Ahliyya Amman University (JO)
- Goethe University Frankfurt (DE)
- University of Modena and Reggio Emilia (IT)
- Vita-Salute San Raffaele University (IT)
- University of Milan (IT)
- Cornell University (US)
- Comprehensive Cancer Center Vienna (AT)
- University Hospital Frankfurt (DE)
- IRCCS Ospedale San Raffaele (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
- Université de Montréal (CA)
- University of Naples Federico II (IT)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- International Journal of Cancer
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1002/ijc.35323
- Citations
- 10
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19